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| INTRODUC TI ON
Hepatitis B virus (HBV) infection is still a constant and serious threat to world health. According to the World Health Organization (WHO), onethird of the world's population has been infected with HBV, and more than 240 million suffer from chronic hepatitis B infection. 1 It is estimated that 15%-40% of patients with hepatitis B will develop cirrhosis, liver failure or hepatocellular carcinoma, thus creating a significant burden to healthcare systems due to high morbidity, mortality and costs of treatment. 2, 3 Hepatitis B vaccination remains the best tool to prevent HBV infection and its complications. During the past 2 decades, universal implementation of HBV vaccine programmes led to a dramatic decrease in the incidence of HBV infection and a subsequent decrease in hepatocellular carcinoma. 4, 5 Currently available HBV vaccines in Europe and North America are formulated with recombinant hepatitis B surface antigen adsorbed to aluminium hydroxide or aluminium phosphate adjuvant. However, after a standard 3-dose vaccination regimen, approximately 5% of vaccinated healthy adults have an inadequate antibody response (anti-HBs titre <10 mIU/mL). [6] [7] [8] [9] [10] In the Netherlands, the vaccination schedule is stopped after a total of 6 hepatitis B vaccinations when development of protective antibodies is lacking. The persons with this deficient antibody response are so-called true nonresponders.
Risk factors for nonresponse include age >40, smoking, obesity, male sex and immunodeficiency. 11, 12 In addition, genetic factors are most likely involved. 13 Thus, there appears to be a medical need for a more immunogenic hepatitis B vaccine to develop an adequate antibody response.
One way to improve the immunogenicity to the current HBV vaccines is to enhance the adjuvant. Adjuvants are thought to improve immune response by (i) causing depot formation at the injection site; (ii) increasing interaction between immunogen and antigenpresenting cell; and (iii) improving antigen presentation to T cells, overall producing a more targeted immune response. This combined vaccine is called HBAI20.
In this study, we assessed the safety and immunogenicity of the HBAI20 vaccine in a randomized controlled trial (RCT) in naïve participants and in an open-label study in true nonresponders.
| PATIENTS AND ME THODS

| Participants
This phase I study involved 2 trials: a double-blinded RCT in naïve
participants and an open-label study in a cohort of true nonresponders. At the first visit, a physical examination was performed and blood and urine sampling were taken, and informed written consent was required to participate in the study. For the RCT, a total of 27 participants were screened and 3 naïve participants were excluded for the following reasons: one with liver function test abnormalities, one with anti-HBs titre >10 mIU/mL and one had a suspicion of Cushing's syndrome. As such, we included 24 healthy HBV vaccine naïve volunteers in the RCT. In the open-label study, we screened and included 10 true nonresponders. True nonresponders had to have received at least 6 HBV vaccinations with a documented nonresponse (anti-HBs <10 mIU/mL) within 6-8 weeks after the last vaccination. All participants were between 18 and 59 years of age.
The study was approved by the local ethics committee and was conducted in accordance with the provisions of the Declaration of
Helsinki and its amendments. Good clinical practice guidelines were followed throughout the study. The study is registered at clinicaltrials.gov (NCT02540538). 
| Vaccines
The experimental vaccine consisted of AI20, containing 20 μg recombinant human IL-2 aggregates adsorbed to 20 μg aluminium hydroxide (CyTuVax B.V., Maastricht, the Netherlands), combined with HBVaxPro©-10 μg (HBAI20). The selection of "20 μg" IL-2 was based on anti-HBs response study in BALB/c and SJL strain mice, determination of the optimal dose in Lewis rats and a toxicology study in New Zealand White rabbits. 15 The control vaccine was the standard HBVaxPro©-10 μg vaccine (Sanofi Pasteur MSD, Haarlem, the Netherlands). HBAI20 was prepared by an unblinded nurse immediately before administration. HBVaxPro©-10 μg was added to the AI20 adjuvant, gently mixed by inversion and aspired with a needle in one syringe (1.3 mL). The label on all vaccines conceals the volume difference between the 2 study vaccines. Both the HBAI20
vaccine and the HBVaxPro©-10 μg vaccine were injected into the deltoid muscle of the nondominant arm by a blinded nurse.
| Study design
In the RCT, 24 healthy HBV vaccine naïve subjects were randomized in a 1:1 ratio into Group 1 (n = 12) and Group 2 (n = 12). Subjects in subjects were asked to measure their temperature and to fill in a symptom diary on the day of first and second vaccination and the subsequent 4 days. They were asked to record any local (pain, im- were recorded throughout the whole study period. All solicited local symptoms were considered as related to vaccination.
| Laboratory assays
Haematological parameters, biochemical parameters including thyroid function and urinalysis were determined using commercially available laboratory methods (Table S1 ). Further measurements of anti-HBs antibodies were assayed using a routine chemiluminescence assay (Anti-HBs, Cobas 8000, Roche, Germany). Titres >10 mIU/mL were considered to be seroprotective.
| Statistical analysis
Log-likelihood chi-square test was used to analyse the differences in adverse events in both trial arms. All data of the outcome variable anti-HBs were 10 log-transformed. To overcome problems with zero values, a score of -0.5 was used. Data were categorized in dichotomies with "0" as nonprotected and "1" as protected. Seroprotection was defined as an anti-HBs titre equal or higher than 10 mlU/mL (in the nontransformed anti-HBs values) after vaccination. Two-by-two cross-tabs were used to analyse the difference of seroprotection between both trial arms. Log-likelihood ratio, chi-square tests and odds ratios (OR) with 95% confidence intervals (CI) were calculated.
Logistic regression analysis was used to correct OR for gender, age and BMI. The original log-transformed data were used in repeated measures ANOVA to analyse the trend of anti-HBs titre. Data have been analysed as intention to treat. The last observation carried forward method was used. All statistics were performed by SPSS version 24.0. P-value of <.05 was used to denote statistical significance.
The 10 nonresponders who participated in the cohort study have been analysed as a separate study.
| RE SULTS
| Demographics
The demographics of the participants in the RCT and open-label study are listed in Table 1 . The healthy HBV vaccine naïve volunteers in the RCT were comparable for mean age and mean body mass index (BMI) in both trial arms. In the open-label study, the anti-HBs titre in 8 of 10 true nonresponders was <2 mIU/mL, 2 persons had a nonprotective anti-HBs titre of 4 and 5 mIU/mL.
| Safety and tolerability of the vaccine
After HBAI20 administration, there were no laboratory abnormalities that would indicate renal, hepatic, thyroid, muscular or bone marrow dysfunctions or detectable inflammatory processes potentially attributable to the vaccine.
In the RCT, there was no significant difference between the HBAI20 group and HBVaxPro©-10 μg group in any adverse events pain at the injection site, P = 1.00. There were no severe local symptoms in the HBAI20 group, and in the HBVaxPro©-10 μg group, the incidence of these was low: severe redness was reported in only one subject. In the open-label study, there was one subject with severe redness and severe induration. All local reactions in both the RCT and open-label study resolved within 4 days after vaccination for 98.5% of subjects.
The frequencies of any and severe solicited general symptoms are shown in Table 3 . Myalgia was the most frequently reported general symptom in both studies (75% in each trial arm in the RCT and 70% in the open-label study). In the RCT, the incidence of severe events was low and only reported in the HBAI20 group. One 
| Immunogenicity of the vaccine
In the RCT, which included naïve seronegative subjects, all patients in the HBVaxPro©-10 μg had protective level of antibodies (P = .16).
In the repeated measures ANOVA analysis, the general trend over the visits 2-7 showed a significant increase in anti-HBs titre (P < .001). Linear trend difference between treatment groups was not significant (P = .237). Age and gender showed no significant differences in the linear trend. The GMTs in the subjects receiving the HBAI20 vaccine vs HBVaxPro©-10 μg vaccine almost reached statistical significance 10 days after the first vaccination with 584.7 mIU/ mL (95% CI: 300.3-869.1) and 369.7 mIU/mL (95% CI: 74.9-664.6), P = .05 (Figure 4) . At visits 5 and 7, older patients had significantly more difficult to build up immune response (P = .014, resp. P < .001).
Effect of gender was not significant.
In the open-label study, HBAI20 vaccine was able to elicit protective anti-HBs titres in 90% of the true nonresponders at 1 month after the third vaccination ( Figure 3 ). The GMTs of anti-HBs antibodies of the nonresponders can be found in Figure 4 .
| D ISCUSS I ON
According to this phase I study, the HBAI20 vaccine seems safe, well-tolerated and may promote more rapid protection against HBV infection. In the RCT, the HBAI20 vaccine achieved seroprotection However, one true nonresponder remained seronegative at month 7. This might be due to chronic local corticosteroid use.
Severe side effects such as hypotension, pulmonary oedema and renal dysfunction have been associated with high-dose intravenous bolus IL-2 in metastatic renal cell cancer. 16 However, the The possibility of inducing specific production of antibodies against hepatitis B surface antigen (anti-HBs) with IL-2 has been studied previously in healthy HBV vaccine naïve participants 21 and in HBV vaccine nonresponders. [22] [23] [24] In a pilot study of Meuer et al 24 6 of only 10 nonresponder patients appeared to respond to concurrent IL-2 administration and HBV revaccination. The patients had renal failure and were on long-term haemodialysis. However, these encouraging results have not been confirmed by other groups. [21] [22] [23] Nonetheless, previous studies assessing IL-2 as an efficient mean of inducing HBsAg-specific immune response have been hampered by the short half-life of IL-2. [21] [22] [23] [24] [25] [26] Our current study is the first report in humans using aggregated IL-2 molecules attached to aluminium 
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